Amit Tiwari
Concepts (339)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Agents | 16 | 2025 | 1175 | 3.250 |
Why?
| Neoplasms | 18 | 2025 | 1234 | 3.140 |
Why?
| Apoptosis | 11 | 2024 | 1092 | 2.450 |
Why?
| Flavonoids | 5 | 2021 | 39 | 2.290 |
Why?
| Drug Resistance, Neoplasm | 7 | 2025 | 314 | 1.570 |
Why?
| Skin Absorption | 2 | 2023 | 24 | 1.530 |
Why?
| Sarcoma, Avian | 3 | 2021 | 10 | 1.460 |
Why?
| Rous sarcoma virus | 3 | 2021 | 4 | 1.460 |
Why?
| Drug Delivery Systems | 11 | 2024 | 143 | 1.430 |
Why?
| Oxidative Stress | 4 | 2021 | 759 | 1.370 |
Why?
| Mitosis | 2 | 2021 | 88 | 1.310 |
Why?
| Cocaine | 2 | 2019 | 173 | 1.170 |
Why?
| Cell Proliferation | 6 | 2024 | 986 | 1.160 |
Why?
| Humans | 67 | 2025 | 49922 | 1.080 |
Why?
| Folic Acid | 2 | 2020 | 137 | 1.020 |
Why?
| Lysosomes | 2 | 2024 | 86 | 0.950 |
Why?
| Carcinoma, Hepatocellular | 2 | 2023 | 194 | 0.910 |
Why?
| Haloperidol | 1 | 2023 | 47 | 0.880 |
Why?
| Colonic Neoplasms | 2 | 2023 | 158 | 0.870 |
Why?
| Hepatitis B | 1 | 2023 | 23 | 0.860 |
Why?
| Polyphenols | 3 | 2019 | 29 | 0.860 |
Why?
| Toxicity Tests | 2 | 2021 | 54 | 0.850 |
Why?
| Biosimilar Pharmaceuticals | 1 | 2022 | 2 | 0.840 |
Why?
| Animals | 25 | 2025 | 13100 | 0.840 |
Why?
| Liver Neoplasms | 2 | 2023 | 329 | 0.830 |
Why?
| Skin | 6 | 2022 | 415 | 0.820 |
Why?
| Heterocyclic Compounds | 1 | 2022 | 29 | 0.810 |
Why?
| Hepatitis C | 1 | 2023 | 80 | 0.800 |
Why?
| Chickens | 3 | 2021 | 108 | 0.790 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 8 | 0.770 |
Why?
| Chalcones | 1 | 2021 | 2 | 0.770 |
Why?
| Neurodegenerative Diseases | 1 | 2022 | 72 | 0.760 |
Why?
| Neoplasm Metastasis | 3 | 2021 | 235 | 0.760 |
Why?
| Endosomes | 1 | 2021 | 33 | 0.750 |
Why?
| Prostatic Neoplasms | 2 | 2024 | 391 | 0.730 |
Why?
| Chemoprevention | 2 | 2017 | 15 | 0.730 |
Why?
| Melanoma | 5 | 2022 | 281 | 0.730 |
Why?
| Dietary Supplements | 2 | 2017 | 437 | 0.720 |
Why?
| Allyl Compounds | 1 | 2020 | 11 | 0.720 |
Why?
| Hydrazones | 1 | 2020 | 6 | 0.720 |
Why?
| Iron | 2 | 2023 | 123 | 0.720 |
Why?
| Biomedical Research | 1 | 2023 | 241 | 0.700 |
Why?
| Cosmetics | 1 | 2020 | 3 | 0.690 |
Why?
| Haptophyta | 1 | 2020 | 5 | 0.690 |
Why?
| Cytokines | 2 | 2024 | 607 | 0.690 |
Why?
| Organic Chemicals | 1 | 2020 | 14 | 0.690 |
Why?
| Healthcare Disparities | 1 | 2023 | 282 | 0.680 |
Why?
| Nucleus Accumbens | 2 | 2022 | 24 | 0.670 |
Why?
| Piperazines | 1 | 2020 | 118 | 0.660 |
Why?
| Iontophoresis | 1 | 2019 | 15 | 0.650 |
Why?
| Th2 Cells | 1 | 2019 | 22 | 0.640 |
Why?
| Alzheimer Disease | 1 | 2022 | 283 | 0.640 |
Why?
| Ultrasonics | 1 | 2019 | 31 | 0.640 |
Why?
| Th1 Cells | 1 | 2019 | 53 | 0.630 |
Why?
| Major Histocompatibility Complex | 1 | 2018 | 12 | 0.620 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2018 | 17 | 0.620 |
Why?
| Uterine Cervical Neoplasms | 1 | 2021 | 276 | 0.620 |
Why?
| Cell Line, Tumor | 9 | 2024 | 1388 | 0.610 |
Why?
| Quinolines | 1 | 2018 | 41 | 0.610 |
Why?
| Prefrontal Cortex | 1 | 2018 | 81 | 0.590 |
Why?
| Liposomes | 5 | 2022 | 52 | 0.590 |
Why?
| Pyrazoles | 1 | 2018 | 111 | 0.570 |
Why?
| Epigenesis, Genetic | 4 | 2025 | 370 | 0.560 |
Why?
| Histone Deacetylase Inhibitors | 4 | 2025 | 57 | 0.560 |
Why?
| Alcohol Drinking | 1 | 2018 | 221 | 0.540 |
Why?
| Nanoparticles | 6 | 2024 | 151 | 0.540 |
Why?
| Tumor Microenvironment | 5 | 2024 | 221 | 0.520 |
Why?
| Pyrimidines | 1 | 2017 | 192 | 0.520 |
Why?
| Ethanol | 1 | 2018 | 335 | 0.510 |
Why?
| Disease Models, Animal | 1 | 2021 | 1411 | 0.510 |
Why?
| Breast Neoplasms | 4 | 2024 | 1183 | 0.460 |
Why?
| Antioxidants | 4 | 2022 | 234 | 0.450 |
Why?
| Gene Expression Regulation | 1 | 2018 | 964 | 0.440 |
Why?
| Eichhornia | 2 | 2022 | 2 | 0.420 |
Why?
| Drug Discovery | 3 | 2022 | 83 | 0.410 |
Why?
| Curcumin | 3 | 2021 | 18 | 0.390 |
Why?
| Female | 14 | 2024 | 26571 | 0.390 |
Why?
| Iron, Dietary | 1 | 2011 | 7 | 0.380 |
Why?
| Hematinics | 1 | 2011 | 13 | 0.380 |
Why?
| Anemia, Iron-Deficiency | 1 | 2011 | 19 | 0.370 |
Why?
| Excipients | 1 | 2010 | 9 | 0.370 |
Why?
| Colorectal Neoplasms | 2 | 2025 | 253 | 0.360 |
Why?
| Peptides | 1 | 2010 | 220 | 0.340 |
Why?
| HEK293 Cells | 2 | 2021 | 216 | 0.330 |
Why?
| Drug Carriers | 3 | 2021 | 69 | 0.310 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 462 | 0.300 |
Why?
| Structure-Activity Relationship | 5 | 2023 | 394 | 0.300 |
Why?
| Proteins | 1 | 2010 | 347 | 0.290 |
Why?
| Nanotubes, Carbon | 2 | 2022 | 68 | 0.290 |
Why?
| Administration, Oral | 3 | 2021 | 433 | 0.280 |
Why?
| RNA, Messenger | 2 | 2020 | 1099 | 0.280 |
Why?
| Biological Availability | 5 | 2024 | 99 | 0.270 |
Why?
| Doxorubicin | 3 | 2024 | 233 | 0.260 |
Why?
| Biomass | 5 | 2022 | 18 | 0.250 |
Why?
| Swine | 2 | 2024 | 396 | 0.250 |
Why?
| Lipids | 3 | 2021 | 145 | 0.240 |
Why?
| Skin Neoplasms | 2 | 2021 | 487 | 0.240 |
Why?
| Drug Synergism | 1 | 2025 | 152 | 0.240 |
Why?
| Limonins | 1 | 2024 | 1 | 0.240 |
Why?
| Polyurethanes | 1 | 2024 | 10 | 0.230 |
Why?
| Movement Disorders | 1 | 2024 | 14 | 0.230 |
Why?
| Hydrogen-Ion Concentration | 2 | 2021 | 168 | 0.230 |
Why?
| Petroleum Pollution | 1 | 2024 | 13 | 0.230 |
Why?
| Acute Pain | 1 | 2024 | 9 | 0.230 |
Why?
| Hydrops Fetalis | 1 | 2023 | 2 | 0.230 |
Why?
| Antibiotics, Antineoplastic | 2 | 2024 | 77 | 0.230 |
Why?
| Eye | 1 | 2024 | 24 | 0.230 |
Why?
| Capsaicin | 1 | 2023 | 16 | 0.220 |
Why?
| Lorazepam | 1 | 2023 | 12 | 0.220 |
Why?
| Kinetics | 5 | 2022 | 632 | 0.220 |
Why?
| Molecular Targeted Therapy | 2 | 2022 | 121 | 0.220 |
Why?
| Cyclosporine | 1 | 2024 | 65 | 0.220 |
Why?
| Diphenhydramine | 1 | 2023 | 20 | 0.220 |
Why?
| Toll-Like Receptor 5 | 1 | 2023 | 4 | 0.220 |
Why?
| Retinal Diseases | 1 | 2024 | 50 | 0.220 |
Why?
| Cell Survival | 2 | 2024 | 590 | 0.220 |
Why?
| Climate Change | 1 | 2023 | 29 | 0.210 |
Why?
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 6 | 0.210 |
Why?
| Cholestasis | 1 | 2023 | 40 | 0.210 |
Why?
| Analgesics | 1 | 2024 | 100 | 0.210 |
Why?
| Cyclodextrins | 1 | 2022 | 18 | 0.210 |
Why?
| Colitis | 1 | 2023 | 51 | 0.210 |
Why?
| Administration, Cutaneous | 2 | 2022 | 53 | 0.210 |
Why?
| Silicon Dioxide | 1 | 2022 | 16 | 0.210 |
Why?
| Glioblastoma | 1 | 2024 | 88 | 0.210 |
Why?
| Signal Transduction | 4 | 2024 | 1608 | 0.210 |
Why?
| Treatment Outcome | 2 | 2023 | 5178 | 0.210 |
Why?
| Biofuels | 1 | 2022 | 5 | 0.200 |
Why?
| Fetus | 1 | 2023 | 214 | 0.200 |
Why?
| Holography | 1 | 2022 | 1 | 0.200 |
Why?
| Nitrogen | 1 | 2022 | 67 | 0.200 |
Why?
| Oncolytic Viruses | 1 | 2022 | 11 | 0.200 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2023 | 183 | 0.200 |
Why?
| Patents as Topic | 1 | 2022 | 9 | 0.200 |
Why?
| Aegle | 1 | 2021 | 1 | 0.200 |
Why?
| Eye Infections | 1 | 2021 | 4 | 0.200 |
Why?
| Oncolytic Virotherapy | 1 | 2022 | 18 | 0.200 |
Why?
| Keratitis | 1 | 2021 | 10 | 0.200 |
Why?
| Delayed-Action Preparations | 3 | 2024 | 55 | 0.190 |
Why?
| Environmental Pollutants | 1 | 2022 | 92 | 0.190 |
Why?
| HT29 Cells | 1 | 2021 | 12 | 0.190 |
Why?
| Medical Oncology | 1 | 2022 | 95 | 0.190 |
Why?
| HCT116 Cells | 1 | 2021 | 23 | 0.190 |
Why?
| Patient Care | 1 | 2022 | 57 | 0.190 |
Why?
| Cathepsins | 1 | 2021 | 7 | 0.190 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2021 | 39 | 0.190 |
Why?
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 14 | 0.190 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2021 | 5 | 0.190 |
Why?
| Phosphatidylcholines | 1 | 2021 | 24 | 0.190 |
Why?
| Male | 7 | 2024 | 25450 | 0.190 |
Why?
| Cricetulus | 1 | 2021 | 107 | 0.190 |
Why?
| CHO Cells | 1 | 2021 | 121 | 0.190 |
Why?
| Water Purification | 1 | 2021 | 9 | 0.190 |
Why?
| Molecular Docking Simulation | 1 | 2021 | 72 | 0.190 |
Why?
| Biological Transport | 1 | 2021 | 170 | 0.180 |
Why?
| Catechols | 1 | 2020 | 8 | 0.180 |
Why?
| Drug Stability | 3 | 2021 | 34 | 0.180 |
Why?
| Artificial Intelligence | 1 | 2022 | 82 | 0.180 |
Why?
| HeLa Cells | 1 | 2021 | 257 | 0.180 |
Why?
| Water Pollutants, Chemical | 1 | 2021 | 43 | 0.180 |
Why?
| Zebrafish | 1 | 2021 | 54 | 0.180 |
Why?
| Lead | 1 | 2020 | 33 | 0.180 |
Why?
| Drug Resistance | 1 | 2020 | 64 | 0.180 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2018 | 131 | 0.180 |
Why?
| Amides | 1 | 2020 | 36 | 0.180 |
Why?
| Severe Acute Respiratory Syndrome | 1 | 2020 | 17 | 0.180 |
Why?
| Prospective Studies | 2 | 2020 | 2345 | 0.180 |
Why?
| Stomach Neoplasms | 1 | 2023 | 187 | 0.180 |
Why?
| Water Loss, Insensible | 1 | 2020 | 1 | 0.170 |
Why?
| Acyclovir | 1 | 2020 | 9 | 0.170 |
Why?
| Anemia | 1 | 2020 | 66 | 0.170 |
Why?
| Prevalence | 1 | 2023 | 956 | 0.170 |
Why?
| Neoadjuvant Therapy | 1 | 2021 | 118 | 0.170 |
Why?
| Autophagy | 1 | 2021 | 165 | 0.170 |
Why?
| Drug Design | 1 | 2020 | 119 | 0.170 |
Why?
| Chemokines | 1 | 2019 | 75 | 0.170 |
Why?
| Lidocaine | 1 | 2020 | 48 | 0.170 |
Why?
| Ceramides | 1 | 2019 | 31 | 0.170 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 205 | 0.170 |
Why?
| Protein Binding | 1 | 2021 | 656 | 0.160 |
Why?
| Cell Movement | 1 | 2020 | 245 | 0.160 |
Why?
| Cell Cycle | 1 | 2020 | 226 | 0.160 |
Why?
| Pandemics | 2 | 2022 | 566 | 0.160 |
Why?
| Drug Resistance, Multiple | 1 | 2019 | 24 | 0.160 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2019 | 34 | 0.160 |
Why?
| Neovascularization, Pathologic | 1 | 2020 | 153 | 0.160 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 994 | 0.160 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2020 | 326 | 0.160 |
Why?
| Dipeptides | 1 | 2018 | 22 | 0.160 |
Why?
| Cell Line | 1 | 2021 | 1010 | 0.160 |
Why?
| Thermogravimetry | 3 | 2022 | 7 | 0.160 |
Why?
| Inflammation Mediators | 1 | 2019 | 110 | 0.150 |
Why?
| Haplotypes | 1 | 2018 | 82 | 0.150 |
Why?
| Lignans | 1 | 2017 | 6 | 0.150 |
Why?
| Hydroxybenzoates | 1 | 2017 | 18 | 0.150 |
Why?
| Cell Nucleus | 1 | 2018 | 186 | 0.140 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 136 | 0.140 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2017 | 49 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2020 | 170 | 0.140 |
Why?
| Stilbenes | 1 | 2017 | 54 | 0.140 |
Why?
| Up-Regulation | 1 | 2019 | 446 | 0.140 |
Why?
| Pregnancy | 2 | 2023 | 2468 | 0.140 |
Why?
| Substance-Related Disorders | 1 | 2022 | 594 | 0.140 |
Why?
| Coronavirus Infections | 1 | 2020 | 179 | 0.140 |
Why?
| Young Adult | 2 | 2020 | 4031 | 0.140 |
Why?
| Molecular Structure | 1 | 2017 | 293 | 0.140 |
Why?
| Gene Expression | 1 | 2019 | 612 | 0.130 |
Why?
| Particle Size | 3 | 2021 | 79 | 0.130 |
Why?
| Rats, Sprague-Dawley | 1 | 2020 | 1578 | 0.130 |
Why?
| Solubility | 3 | 2021 | 72 | 0.130 |
Why?
| Adult | 4 | 2023 | 13355 | 0.120 |
Why?
| Obesity | 1 | 2023 | 1096 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 1 | 2017 | 1354 | 0.110 |
Why?
| Pharmaceutical Preparations | 2 | 2024 | 76 | 0.110 |
Why?
| Lipid Bilayers | 2 | 2022 | 12 | 0.100 |
Why?
| Rats | 1 | 2018 | 3273 | 0.100 |
Why?
| Mice | 4 | 2023 | 5658 | 0.100 |
Why?
| Brain | 1 | 2019 | 1310 | 0.100 |
Why?
| Polymers | 2 | 2023 | 42 | 0.100 |
Why?
| Polyethylene Glycols | 2 | 2022 | 85 | 0.090 |
Why?
| Drug Compounding | 2 | 2021 | 26 | 0.090 |
Why?
| Drug Storage | 1 | 2010 | 2 | 0.090 |
Why?
| Dendrimers | 1 | 2010 | 2 | 0.090 |
Why?
| Microspheres | 1 | 2010 | 26 | 0.090 |
Why?
| Chemistry, Pharmaceutical | 1 | 2010 | 33 | 0.090 |
Why?
| Superoxide Dismutase | 1 | 2011 | 113 | 0.090 |
Why?
| Immunotherapy | 2 | 2023 | 235 | 0.090 |
Why?
| Glutathione | 1 | 2011 | 296 | 0.090 |
Why?
| Analysis of Variance | 1 | 2011 | 552 | 0.080 |
Why?
| Inflammation | 2 | 2024 | 603 | 0.080 |
Why?
| Prognosis | 2 | 2024 | 1956 | 0.080 |
Why?
| Multiple Myeloma | 1 | 2021 | 2916 | 0.070 |
Why?
| Organoplatinum Compounds | 1 | 2025 | 15 | 0.060 |
Why?
| Platinum Compounds | 1 | 2025 | 11 | 0.060 |
Why?
| Administration, Ophthalmic | 1 | 2024 | 1 | 0.060 |
Why?
| Ophthalmic Solutions | 1 | 2024 | 19 | 0.060 |
Why?
| Dopaminergic Neurons | 1 | 2024 | 18 | 0.060 |
Why?
| Methyltransferases | 1 | 2024 | 29 | 0.060 |
Why?
| Nanotechnology | 1 | 2024 | 36 | 0.060 |
Why?
| Emulsions | 1 | 2024 | 25 | 0.060 |
Why?
| Single-Cell Analysis | 1 | 2024 | 63 | 0.060 |
Why?
| Anthracyclines | 1 | 2024 | 29 | 0.060 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 75 | 0.060 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2024 | 51 | 0.060 |
Why?
| Homozygote | 1 | 2023 | 56 | 0.060 |
Why?
| Droughts | 1 | 2023 | 9 | 0.060 |
Why?
| Zinc | 1 | 2024 | 52 | 0.060 |
Why?
| Succinic Acid | 1 | 2023 | 3 | 0.060 |
Why?
| India | 1 | 2023 | 52 | 0.060 |
Why?
| Dextran Sulfate | 1 | 2023 | 10 | 0.060 |
Why?
| Inulin | 1 | 2023 | 9 | 0.060 |
Why?
| Agriculture | 1 | 2023 | 18 | 0.060 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2024 | 67 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2024 | 163 | 0.050 |
Why?
| Patient Selection | 1 | 2025 | 254 | 0.050 |
Why?
| Deuterium | 1 | 2023 | 43 | 0.050 |
Why?
| Excitatory Amino Acid Transporter 2 | 1 | 2022 | 2 | 0.050 |
Why?
| Glutamates | 1 | 2022 | 22 | 0.050 |
Why?
| beta-Lactams | 1 | 2022 | 30 | 0.050 |
Why?
| Cardiolipins | 1 | 2022 | 2 | 0.050 |
Why?
| Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 19 | 0.050 |
Why?
| Porosity | 1 | 2022 | 31 | 0.050 |
Why?
| Daunorubicin | 1 | 2022 | 12 | 0.050 |
Why?
| Bile Acids and Salts | 1 | 2023 | 76 | 0.050 |
Why?
| Phosphorylcholine | 1 | 2022 | 20 | 0.050 |
Why?
| MCF-7 Cells | 1 | 2022 | 62 | 0.050 |
Why?
| Anaerobiosis | 1 | 2022 | 18 | 0.050 |
Why?
| Methane | 1 | 2022 | 8 | 0.050 |
Why?
| Cell Transformation, Neoplastic | 1 | 2023 | 181 | 0.050 |
Why?
| Silver | 1 | 2022 | 48 | 0.050 |
Why?
| Digestion | 1 | 2022 | 27 | 0.050 |
Why?
| Ligands | 1 | 2022 | 203 | 0.050 |
Why?
| Lecithins | 1 | 2022 | 1 | 0.050 |
Why?
| Phenylethyl Alcohol | 1 | 2022 | 5 | 0.050 |
Why?
| Immunosuppressive Agents | 1 | 2024 | 226 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2022 | 94 | 0.050 |
Why?
| Chemokine CCL5 | 1 | 2021 | 8 | 0.050 |
Why?
| Surface-Active Agents | 1 | 2022 | 10 | 0.050 |
Why?
| Solid Waste | 1 | 2021 | 2 | 0.050 |
Why?
| Glutamic Acid | 1 | 2022 | 108 | 0.050 |
Why?
| Cholesterol | 1 | 2022 | 148 | 0.050 |
Why?
| Immunoglobulins, Intravenous | 1 | 2022 | 55 | 0.050 |
Why?
| RNA, Viral | 1 | 2022 | 124 | 0.050 |
Why?
| Mammals | 1 | 2022 | 57 | 0.050 |
Why?
| Microscopy | 1 | 2022 | 58 | 0.050 |
Why?
| Cadaver | 1 | 2022 | 96 | 0.050 |
Why?
| Adenosine | 1 | 2022 | 70 | 0.050 |
Why?
| Histones | 1 | 2023 | 295 | 0.050 |
Why?
| RNA | 1 | 2022 | 169 | 0.050 |
Why?
| Combined Modality Therapy | 1 | 2023 | 638 | 0.050 |
Why?
| Toll-Like Receptor 4 | 1 | 2021 | 51 | 0.050 |
Why?
| Snakes | 1 | 2021 | 1 | 0.050 |
Why?
| Gallbladder Neoplasms | 1 | 2021 | 7 | 0.050 |
Why?
| Necrosis | 1 | 2022 | 175 | 0.050 |
Why?
| Amino Acids | 1 | 2023 | 363 | 0.050 |
Why?
| Biliary Tract Neoplasms | 1 | 2021 | 9 | 0.050 |
Why?
| Cholecystitis | 1 | 2021 | 12 | 0.050 |
Why?
| Transcription Factor RelA | 1 | 2021 | 31 | 0.050 |
Why?
| Adsorption | 1 | 2021 | 18 | 0.050 |
Why?
| Permeability | 1 | 2021 | 68 | 0.050 |
Why?
| Renal Dialysis | 1 | 2022 | 170 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 584 | 0.050 |
Why?
| Cell Death | 1 | 2022 | 174 | 0.050 |
Why?
| Half-Life | 1 | 2021 | 85 | 0.050 |
Why?
| Disease Susceptibility | 1 | 2021 | 88 | 0.050 |
Why?
| Drug Combinations | 1 | 2021 | 126 | 0.050 |
Why?
| Fruit | 1 | 2021 | 113 | 0.050 |
Why?
| Phenotype | 1 | 2023 | 728 | 0.050 |
Why?
| Immunity, Innate | 1 | 2021 | 104 | 0.050 |
Why?
| Click Chemistry | 1 | 2020 | 3 | 0.050 |
Why?
| Brain Neoplasms | 1 | 2024 | 282 | 0.050 |
Why?
| Carbamates | 1 | 2020 | 15 | 0.040 |
Why?
| Mice, Knockout | 1 | 2023 | 835 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 212 | 0.040 |
Why?
| Urea | 1 | 2020 | 77 | 0.040 |
Why?
| Limit of Detection | 1 | 2020 | 15 | 0.040 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2021 | 213 | 0.040 |
Why?
| Triazoles | 1 | 2020 | 112 | 0.040 |
Why?
| Disease Management | 1 | 2021 | 175 | 0.040 |
Why?
| Quercetin | 1 | 2019 | 14 | 0.040 |
Why?
| Catechin | 1 | 2019 | 12 | 0.040 |
Why?
| DNA Methylation | 1 | 2024 | 544 | 0.040 |
Why?
| Epidermis | 1 | 2019 | 28 | 0.040 |
Why?
| NF-kappa B | 1 | 2021 | 315 | 0.040 |
Why?
| Calorimetry, Differential Scanning | 1 | 2019 | 8 | 0.040 |
Why?
| Bone Marrow | 1 | 2021 | 351 | 0.040 |
Why?
| Pyridines | 1 | 2020 | 133 | 0.040 |
Why?
| Microscopy, Electron, Scanning | 1 | 2019 | 48 | 0.040 |
Why?
| Linear Models | 1 | 2020 | 274 | 0.040 |
Why?
| Xenorhabdus | 1 | 2018 | 1 | 0.040 |
Why?
| Chromatography, Thin Layer | 1 | 2018 | 24 | 0.040 |
Why?
| Tissue Distribution | 1 | 2019 | 163 | 0.040 |
Why?
| Mutation | 1 | 2024 | 1292 | 0.040 |
Why?
| Stereoisomerism | 1 | 2018 | 101 | 0.040 |
Why?
| Cell Membrane | 1 | 2019 | 249 | 0.040 |
Why?
| Middle Aged | 2 | 2023 | 12289 | 0.040 |
Why?
| Anti-Bacterial Agents | 1 | 2022 | 742 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2020 | 1182 | 0.030 |
Why?
| Aged | 1 | 2021 | 9448 | 0.020 |
Why?
|
|
Tiwari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|